Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17263335 | 0.91 | SCD (0.42) | HDAC1KLKB1KLK1SCDMAPT | |
| SCHEMBL1767462 | 0.90 | SCD (0.41) | HDAC1KLKB1SCD | |
| SCHEMBL1767688 | 0.89 | SCD (0.50) | HDAC1KLKB1KLK1SCDMAPT | |
| SCHEMBL1767488 | 0.87 | HDAC1 (0.49) | HDAC1SCDKDM1AROCK2 | |
| SCHEMBL1767539 | 0.86 | ROCK2 (0.42) | HDAC1KLKB1SCDTSHRROCK2 | |
| SCHEMBL17263334 | 0.81 | SCD (0.44) | HDAC1SCDMAPTKDM1A | |
| SCHEMBL1767489 | 0.80 | SCD (0.43) | HDAC1KLKB1SCD | |
| SCHEMBL1767515 | 0.79 | SCD (0.52) | HDAC1KLKB1KLK1SCDMAPT | |
| SCHEMBL17263326 | 0.77 | SCD (0.45) | HDAC1SCDMAPTROCK2 | |
| SCHEMBL1767533 | 0.77 | SCD (0.45) | HDAC1KLKB1SCDMAPTROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | HDAC1 782/4885KLKB1 1515/4885KLK1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.